Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00005617
First received: May 2, 2000
Last updated: July 27, 2012
Last verified: July 2012
  Purpose

RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV, or relapsed malignant melanoma.


Condition Intervention Phase
Melanoma
Biological: dendritic cell-MART-1 peptide vaccine
Procedure: leukapheresis
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase I Trial Testing Mart-1 Peptide Immunization in Malignant Melanoma

Resource links provided by NLM:


Further study details as provided by Jonsson Comprehensive Cancer Center:

Study Start Date: July 1997
Primary Completion Date: June 2002 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A
No. DC: 10^5 Route of Immunization: ID
Biological: dendritic cell-MART-1 peptide vaccine
Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.
Procedure: leukapheresis
Patients require a single leukapheresis to obtain 2x10^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.
Experimental: Group B
No. DC: 10^5 Route of Immunization: IV
Biological: dendritic cell-MART-1 peptide vaccine
Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.
Procedure: leukapheresis
Patients require a single leukapheresis to obtain 2x10^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.
Experimental: Group C
No. DC: 10^6 Route of Immunization: ID
Biological: dendritic cell-MART-1 peptide vaccine
Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.
Procedure: leukapheresis
Patients require a single leukapheresis to obtain 2x10^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.
Experimental: Group D
No. DC: 10^6 Route of Immunization: IV
Biological: dendritic cell-MART-1 peptide vaccine
Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.
Procedure: leukapheresis
Patients require a single leukapheresis to obtain 2x10^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.
Experimental: Group E
No. DC: 10^7 Route of Immunization: ID
Biological: dendritic cell-MART-1 peptide vaccine
Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.
Procedure: leukapheresis
Patients require a single leukapheresis to obtain 2x10^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.
Experimental: Group F
No. DC: 10^7 Route of Immunization: IV
Biological: dendritic cell-MART-1 peptide vaccine
Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.
Procedure: leukapheresis
Patients require a single leukapheresis to obtain 2x10^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.

Detailed Description:

OBJECTIVES:

  • Determine the safety of administering MART-1 peptide-pulsed dendritic cells to patients with stage IV or relapsed malignant melanoma.
  • Determine the immunological and clinical responses in this patient population after this therapy.

OUTLINE: This is a dose-escalation study.

Patients undergo leukapheresis between days -14 to -8. Mononuclear cells are isolated, used to generate dendritic cells (DC), and then pulsed with MART-1 peptide. Patients are vaccinated with MART-1 peptide-pulsed DC either IV or intradermally on days 0, 14, and 28.

Cohorts of 3-6 patients receive escalating doses of MART-1 peptide-pulsed DC until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.

Patients are followed until death.

PROJECTED ACCRUAL: A total of 18-24 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults over the age of 18 with malignant melanoma.
  • HLA-A2.1 positive and express MART-1, as assessed by either RT-PCR or by immunohistochemistry
  • Tumor stages T3N0M0 or greater are eligible for this trial according to the following:

    1. I (<.75 to 1.5 mm or Clark level III-T1-2N0M0-)—not eligible
    2. II (1.5 to 4 mm or level IV-T3N0M0-)—eligible
    3. III (limited nodal metastasis involving one regional lymph node basin, or fewer than 5 in-transit metastasis -TxN1M0-)—eligible
    4. IV (advanced regional metastasis -TxN2M0- or any distant metastasis -TxNxM1-)—eligible
    5. Relapsed melanoma—eligible
  • Patients previously treated with any form of therapy for either metastatic, relapsed or primary melanoma are eligible for this trial, provided that previous treatment was completed >30 days prior to enrollment
  • Both male and females may be enrolled. Premenopausal females must have a negative pregnancy test prior to treatment
  • Karnofsky Performance Status greater than or equal to 70 percent
  • No previous evidence of class 3 or greater New York Heart Association cardiac insufficiency or coronary artery disease
  • No previous evidence of opportunistic infection
  • A minimum of 30 days must have elapsed since the completion of prior chemotherapy, immunotherapy or radiation therapy
  • Adequate baseline hematological function as assessed by the following laboratory values within 30 days prior to study entry (day -30 to 0):

    1. Hemoglobin >9.0 g/dl
    2. Platelets > 100000/mm3
    3. WBC > 3000/mm3
    4. Absolute Neutrophil Count > 1000/mm3
  • Positive skin test to common antigens (tetanus and candida)
  • Ability to give informed consent

Exclusion Criteria:

  • Lactating females and females of child-bearing potential must have negative serum beta-HCG pregnancy test
  • Acute infection: any acute viral, bacterial, or fungal infection which requires specific therapy. Acute therapy must have been completed within 14 days of prior to study treatment
  • HIV-infected patients
  • Acute medical problems such as ischemic heart or lung disease that may be considered an unacceptable anesthetic or operative risk
  • Patients with any underlying conditions which would contraindicate therapy with study treatment (or allergies to reagents used in this study)
  • Patients with organ allografts
  • Uncontrolled CNS metastasis. Patients with CNS metastasis will be eligible if they have received CNS irradiation to control local tumor growth
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00005617

Locations
United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Investigators
Principal Investigator: John A Glaspy, MD Jonsson Comprehensive Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00005617     History of Changes
Other Study ID Numbers: CDR0000067754, P30CA016042, UCLA-9508375, NCI-H00-0050
Study First Received: May 2, 2000
Last Updated: July 27, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Jonsson Comprehensive Cancer Center:
stage IV melanoma
recurrent melanoma

Additional relevant MeSH terms:
Melanoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas

ClinicalTrials.gov processed this record on November 24, 2014